Cardionovum

Be up
to date.

Latest press release

CARDIONOVUM GmbH, a medical technology company developing and commercializing innovative medical devices such as drug-coated balloons and drug-eluting stents for the treatment of coronary and peripheral artery disease, announced today the enrollment of the first patient in the MAGNIFICENT trial.

Cardionovum experiences increase in demand for its innovative, and next generation „RESTORE Paclitaxel-releasing coronary balloon dilatation catheter.“ The American Journal of Cardiology, issue December 2015, published study results on the efficacy and safety of Paclitaxel coated balloon catheters for the treatment of in-stent restenosis in high risk patients. The RESTORE DEB showed significant superiority with lowest incidence of restenosis, if compared to other contemporary coronary DEBs.

Dr. Jean Paul de Vries (PI) presented the patient study results of the multi-center randomized RAPID trial.

Cardionovum prepares for a first international publication on 6-12 months FU patient results from the ongoing APERTO clinical study program. The APERTO Paclitaxel-releasing high pressure shunt balloon dilatation catheter was exclusively designed to treat shunt stenosis of hemodialysis patients.

Upcoming events

Currently there are no events.

Latest events

Cardionovum® at 23rd Union Conference of the Swiss Societies for Vascular Diseases

Cardionovum® is pleased to invite you to visit us at booth #11

Location:

Beaulieu SA
Avenue des Bergières 10
CH-1004
Lausanne, Switzerland

Date: Nov 15, 2023–Nov 17, 2023

Cardionovum® at DGK HERZTAGE 2023

Cardionovum® is pleased to invite you to visit us at booth #036

Location:

World Conference Center Bonn (WCCB)
Platz der Vereinten Nationen 2
53113 Bonn

Date: Oct 05, 2023–Oct 07, 2023

Cardionovum® at GISE 2023

Cardionovum® is pleased to invite you to visit us at booth #11

Location:

Allianz MiCo - Milano Congressi
South Wing
Viale Eginardo - Gate 2
20149 Milano, Italy

Date: Oct 03, 2023–Oct 06, 2023

go top